Researchers are calling for more investment in medicinal cannabis research. They say that more research is needed to fully understand the benefits and risks of medicinal cannabis. (Source: Marijuana Business Daily, November 25, 2023)

Indeed, researchers are calling for more investment in medicinal cannabis research¹. They believe that more research is needed to fully understand the benefits and risks of medicinal cannabis¹. This call comes at a time when the interest in and use of medicinal cannabis is growing globally¹²³⁴.

The researchers’ call for more investment could potentially lead to increased funding for research into medicinal cannabis, thereby contributing to a better understanding of its therapeutic potential and risks¹²³⁴. However, it’s important to note that conducting research in this field involves navigating complex regulatory environments and ethical considerations¹²³⁴.

For more details, you can refer to the source: Marijuana Business Daily.

Learn more:

1. nihr.ac.uk2. labmanager.com3. news.sky.com4. leafly.com5. nihr.ac.uk

Medical Cannabis Research Regulations: Medical cannabis research is regulated by various laws and guidelines. In the UK, cannabis-based medicines were rescheduled under UK law in 2018, allowing doctors to prescribe these treatments for a wide range of conditions¹. However, the Misuse of Drugs Act 1971 still classifies Cannabis as a controlled drug, making it illegal for people to possess, supply, produce, or import/export controlled drugs².

In the United States, researchers need to work with the FDA and submit an Investigational New Drug (IND) application to the Center for Drug Evaluation and Research (CDER) to conduct clinical research that can lead to an approved new drug, including research using materials from plants such as cannabis³. Federal restrictions on clinical cannabis research result from its legal status as defined by the Controlled Substances Act and international treaties⁴.

Medical Cannabis Research Benefits: Research suggests that THC and other cannabinoids may have potential in the treatment of pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions⁵. Some studies show that marijuana may provide relief for patients with a slew of conditions, such as anxiety, chronic pain, and even cancer⁶.

Medical Cannabis Research Risks: The potential harms of cannabis-based medicines may outweigh benefits. Adverse effects were reported in most reviews comparing cannabis with placebo, and in many of the reviews comparing cannabis to active drugs. Minor adverse effects (e.g., drowsiness, dizziness) were common and reported in over half of the reviews. Serious harms were not as common, but were reported in some reviews that reported on adverse effects⁷.

Medical Cannabis Research Future Trends: Cannabis research is expected to continue evolving in the future. Some of the anticipated trends include modern cultivation and production techniques, an increasing focus on the therapeutic potential of cannabidiol (CBD), minor cannabinoids taking center stage, new and improved delivery systems for cannabis-based medicines, and cannabis research expanding due to changes in the legal landscape⁸.

Learn more:

1. gov.uk2. commonslibrary.parliament.uk3. fda.gov4. academic.oup.com5. nida.nih.gov6. discovermagazine.com7. systematicreviewsjournal.biomedcentral.com8. labmanager.com9. openaccessgovernment.org10. dechert.com11. pharmout.net12. arnoldporter.com13. leafly.com14. ourcrowd.com15. globalizationandhealth.biomedcentral.com16. insights.mjbizdaily.com17. mjbizdaily.com18. mjbizdaily.com19. mjbizdaily.com20. imperial.ac.uk21. cannabisresearchuk.com22. nccih.nih.gov23. news.sky.com24. nccih.nih.gov25. drugscience.org.uk26. nida.nih.gov27. leafly.com28. healtheuropa.com29. weedmaps.com30. thecannabisscientist.com31. bmj.com32. nida.nih.gov33. nhs.uk34. nccih.nih.gov35. natlawreview.com36. doi.org37. ruor.uottawa.ca

The UK government has launched a new consultation on the regulation of medicinal cannabis. The consultation seeks views on a number of issues, including the licensing of medicinal cannabis producers, the pricing of medicinal cannabis products, and the advertising of medicinal cannabis. (Source: GOV.UK, November 27, 2023)

The UK government has launched a new consultation on the regulation of medicinal cannabis. This consultation aims to gather opinions on various aspects of medicinal cannabis regulation, including:

• The licensing of medicinal cannabis producers: This could involve determining who is allowed to grow and distribute medicinal cannabis, what qualifications or standards they must meet, and how these licenses are monitored and enforced.
• The pricing of medicinal cannabis products: This could involve discussions on how medicinal cannabis products should be priced, whether there should be a standard pricing model, and how this would affect accessibility for patients.
• The advertising of medicinal cannabis: This could involve setting guidelines for how medicinal cannabis can be advertised, what claims can be made about its effects, and how to ensure that advertising is ethical and not misleading.

It’s a significant step towards establishing a clear and effective regulatory framework for medicinal cannabis in the UK. The outcomes of this consultation could have far-reaching implications for patients, healthcare providers, and the medicinal cannabis industry as a whole. It’s important for all stakeholders to participate in this consultation to ensure their views and experiences are taken into account.

Here are some sources that provide information on the UK government’s consultation on medicinal cannabis:

1. Economic contribution of medicinal cannabis – House of Commons Library: This source provides information on the economic contribution of medicinal cannabis. It mentions a Westminster Hall debate on the economic contribution of medicinal cannabis scheduled for Thursday 20 April 2023 at 3pm. The debate will be led by the Rt Hon David Mundell MP.
2. Medicinal cannabis: information and resources – GOV.UK: This is a collection of resources and interim guidance on the law for healthcare professionals related to medicinal cannabis.
3. Drugs policy and medicinal cannabis report: government response: This is the government’s response to the Health and Social Care Select Committee report on drugs policy and medicinal cannabis.
4. Medical cannabis in the UK and the industry’s future – Government: This source discusses the future of the medical cannabis industry in the UK and the role of UK-based cannabis companies.

Learn more:

1. commonslibrary.parliament.uk2. gov.uk3. gov.uk4. openaccessgovernment.org

Don’t Count on CBD Beverages to Alleviate Anxiety The stark disparity between commercial CBD drinks, oils, treats, and scientifically-backed medical products is worth noting.

CBD—cannabidiol—has soared in popularity as a wellness trend, drawing the interest of an estimated six million Brits. Forecasts suggest that by 2025, the UK market for CBD could hit the £1 billion mark. The market is flush with CBD goods—ranging from tinctures, patches, e-liquids, to consumable drinks and edibles, as well as topicals like creams, shampoos, and gels—purportedly addressing issues from anxiety and sleep disturbances to muscle aches. Even mainstream supermarkets like Sainsbury’s are now stocking CBD beverages from brands like Trip, self-proclaimed as “the UK’s #1 CBD brand.”

Trip’s marketing suggests that “many people use CBD to help manage stress and anxiety”—portraying their product as a fizzy stress-reliever for the mind, body, and spirit. However, there’s a substantial gap between the non-medical CBD found in products like those from Trip and the type of CBD that’s actually being rigorously studied for potential health benefits. Trip themselves admit on their site that their drinks are “not intended to diagnose, treat, cure or prevent disease.”

Dr. Simon Erridge, a cannabis-based medicine researcher from Imperial College London, argues that over-the-counter companies should not equate their offerings with particular health benefits. “In the UK, pharmaceutical-grade medical cannabis must be prescribed by a consultant, with stringent quality controls,” he explains. These products have undergone intensive testing to ensure they adhere to specific pre-defined pharmaceutical standards, particularly in terms of CBD accuracy.

In essence, the gap between pharmaceutical-grade CBD, which boasts promising research-backed benefits, and the variety found in everyday health stores or groceries, is vast. “Studies have primarily focused on pharmaceutical products, not wellness ones—especially those infused in food or beverages—so claiming they could treat anxiety, for example, seems quite a leap,” Erridge clarifies.

Furthermore, even assuming non-pharmaceutical CBD had proven efficacy for anxiety, the dosages in consumer products pale in comparison to those under scientific investigation. For instance, a single Trip drink from Sainsbury’s, retailing at £2, contains just 15mg of CBD. In contrast, research indicates that daily doses of 300-600mg of CBD might be beneficial for anxiety, albeit further study is needed.

If Trip’s cans contained pharmaceutical-grade CBD, which they don’t, one would need to consume an unrealistic 20 to 40 cans a day to match the therapeutic doses researched, which would incur a staggering weekly cost of £280 to £560. The ethics behind Trip’s marketing approach, which teases the potential anti-anxiety effects of CBD yet delivers non-pharmaceutical grade dosages, come into question.

Trip did not comment on these points when approached. Their website, however, references a study by Dr. Julie Moltke, a clinical researcher and industry consultant in the UK’s medicinal cannabis sector, citing that “75 percent of CBD users for stress relief experienced benefits.” Moltke emphasizes that her observational study was not a randomised controlled trial and calls for more research before drawing robust conclusions.

Trip is not the sole brand linked to the therapeutic merits of pharmaceutical CBD. Reports—such as one by the World Health Organization on CBD’s potential benefits for various diseases—have been used to market commercial CBD products despite their non-pharmaceutical grade and small doses. Even VICE reviews admitting relief from products like Kloris’ CBD patches, which contain a mere 16mg of non-pharmaceutical CBD, are compelled to remind consumers that these items “are not medicines.”

In the US, the FDA has made it illegal to pair medical claims with non-pharmaceutical CBD supplements, highlighting the risk that such unsubstantiated claims pose. Not only might this be illegal, but it may also compromise public health, given that these products have not been proven to be effective or safe.

The hidden hazards of CBD surpass merely monetary losses by those seeking authentic health solutions. According to medical researcher Safeena Minhas from The University of Manchester, the side effects of CBD—such as drowsiness, diarrhea, appetite suppression, and at high doses, liver damage—are understated, with many wellness sites failing to mention potential adverse impacts.

Currently, evidence strongly supports CBD treatment for only one condition: treatment-resistant epilepsy in children, for which pharmaceutical-grade CBD is prescribable by the NHS. Minhas advises consumers to be discerning about CBD sources and contents, as misleading advertising abounds, and a recent study revealed that most UK non-pharmaceutical CBD products fell short on their advertised potencies.

To acquire “the good stuff”—pharmaceutical-grade CBD—patients typically must turn to one of the UK’s 40 private clinics authorized to prescribe it, ensuring a doctor’s oversight and compatibility with other medications.

Dr. Erridge concludes, emphasizing the importance of consulting a trained professional or clinic rather than relying on over-the-counter CBD oils that lack evidence of efficacy and quality. Therefore, it seems unlikely that a Sainsbury’s-sourced can of CBD is going to serve as a panacea for your anxiety.

You might be interested in Cannabidiol, the key ingredient in commercial CBD drinks, which has gained significant popularity as a wellness trend. However, it’s important to note the limited efficacy of these products for anxiety relief. Speaking of anxiety, you might also be interested in Anxiety as a common mental health condition that affects many individuals. It’s crucial to consult a trained professional or clinic for evidence-based treatments rather than relying on over-the-counter CBD oils. Additionally, to understand the discrepancies in CBD product potencies, you can

You might be interested in anxiety, a common mental health condition that affects many individuals. Speaking of anxiety, you might also be interested in consulting a trained professional or clinic for evidence-based treatments rather than relying on over-the-counter CBD oils. Additionally, to understand the discrepancies in CBD product potencies, you can explore more about Cannabidiol, the key ingredient in commercial CBD drinks, which has gained significant popularity as a wellness trend. However, it’s important to note the limited efficacy of these products for anxiety relief. If you want to learn more, you can visit the Wikipedia article on Anxiety and the

Categories: Uncategorized

MJBizCon is one of the largest and most influential conferences in the cannabis industry. It brings together professionals, entrepreneurs, investors, and companies from all sectors of the cannabis space to network, learn, and collaborate. The event is held annually and has grown steadily since its inception in 2012. MJBizCon provides a platform for industry players to showcase their products and services, share insights, and discuss the latest trends and developments in the cannabis world. The conference features an expansive exhibit hall where attendees can explore an array of cannabis-related products, technologies, and innovations. From cultivation and extraction equipment to packaging solutions and software platforms, MJBizCon covers all aspects of the cannabis supply chain. One of the main highlights of MJBizCon is its comprehensive educational program. The conference hosts a wide range of expert-led sessions, workshops, and panel discussions covering topics such as regulatory updates, market trends, investment opportunities, marketing strategies, and best practices for cannabis businesses. The educational sessions are designed to provide attendees with valuable insights and practical knowledge that can help them navigate the complex and ever-evolving cannabis industry. Moreover, MJBizCon offers unparalleled networking opportunities. With thousands of professionals in attendance, the conference provides a conducive environment for industry stakeholders to connect, establish partnerships, and explore potential collaborations. The event also includes various networking events, such as receptions and after-parties, where attendees can further engage with like-minded individuals and expand their professional network. In recent years, MJBizCon has expanded beyond its flagship event in Las Vegas to include additional conferences and expos in different locations around the world. This global expansion has allowed the conference to connect with industry professionals from various regions and facilitate knowledge sharing on a global scale. Overall, MJBizCon plays a pivotal role in shaping the cannabis industry by bringing together key players and fostering collaboration and innovation. It serves as a platform for entrepreneurs to showcase their products, investors to discover new opportunities, and industry professionals to stay updated on the latest advancements and trends. With its robust educational program, expansive exhibit hall, and unmatched networking opportunities, MJBizCon continues to be a must-attend event for anyone involved or interested in the cannabis industry.

MJBizCon 2023, the largest cannabis industry event in the world, opened this week with hopes for a brighter future for the industry. The event will feature a number of panels and discussions on the latest trends in the cannabis industry, as well as networking opportunities for cannabis businesses. Indeed, MJBizCon 2023, the world’s largest cannabis industry event, has opened with optimism for a brighter future for the industry¹. The event will host a variety of panels and discussions on the latest trends in the cannabis industry². It also provides networking opportunities for cannabis businesses². This is a significant event for anyone involved in the cannabis industry, offering insights into the current state of the industry and future trends¹². For more details, you can refer to the source: MJBizDaily.

Learn more:

1. mjbizdaily.com2. mjbizconference.com3. mjbizdaily.com4. mjbizdaily.com5. finance.yahoo.com6. mjbizconference.com7. mjbizdaily.com

Stress Need for Risk-Taking: Cannabis industry stakeholders are optimistic about the prospects for the end of the 280E tax code provision, which currently prohibits cannabis businesses from deducting their business expenses from their federal income taxes. The stakeholders believe that the end of 280E would be a major boon for the cannabis industry, as it would allow businesses to keep more of their profits and invest more in growth.

Key Points

• Cannabis industry stakeholders are expressing optimism about the potential repeal of 280E, a provision in the U.S. tax code that prohibits cannabis businesses from deducting their business expenses from their federal income taxes.
• The repeal of 280E would be a significant boon for the cannabis industry, allowing businesses to retain more of their profits and invest in growth.
• However, stakeholders acknowledge that the cannabis industry still faces challenges, including regulatory hurdles and a lack of access to capital.

Additional Details

• The optimism among cannabis industry stakeholders stems from recent developments in the U.S. Congress, where there is growing bipartisan support for cannabis reform.
• Stakeholders also point to the increasing legalization of cannabis at the state level as evidence of the growing acceptance of the industry.
• Despite the positive outlook, stakeholders caution that the cannabis industry is still in its early stages of development and faces numerous challenges.
• These challenges include navigating complex regulations, securing access to capital, and building consumer trust.

Overall, the news article suggests that the cannabis industry is poised for significant growth in the coming years. However, the industry must overcome a number of challenges to reach its full potential.

Summary with Dates and Sources

Cannabis Industry Stakeholders Upbeat About Prospects for End of 280E, Stress Need for Risk-Taking

Date: November 22, 2023

Source: MJBizDaily

Key Points

• Cannabis industry stakeholders are expressing optimism about the potential repeal of 280E, a provision in the U.S. tax code that prohibits cannabis businesses from deducting their business expenses from their federal income taxes. (MJBizDaily, November 22, 2023)
• The repeal of 280E would be a significant boon for the cannabis industry, allowing businesses to retain more of their profits and invest in growth. (MJBizDaily, November 22, 2023)
• However, stakeholders acknowledge that the cannabis industry still faces challenges, including regulatory hurdles and a lack of access to capital. (MJBizDaily, November 22, 2023)

Additional Details

• The optimism among cannabis industry stakeholders stems from recent developments in the U.S. Congress, where there is growing bipartisan support for cannabis reform. (MJBizDaily, November 22, 2023)
• Stakeholders also point to the increasing legalization of cannabis at the state level as evidence of the growing acceptance of the industry. (MJBizDaily, November 22, 2023)
• Despite the positive outlook, stakeholders caution that the cannabis industry is still in its early stages of development and faces numerous challenges. (MJBizDaily, November 22, 2023)
• These challenges include navigating complex regulations, securing access to capital, and building consumer trust. (MJBizDaily, November 22, 2023)

Overall, the news article suggests that the cannabis industry is poised for significant growth in the coming years. However, the industry must overcome a number of challenges to reach its full potential.

You might be interested in exploring more about the cannabis industry and its potential growth. Speaking of the cannabis industry, you might be interested in Cannabis Industry on Wikipedia. This article provides an overview of the industry, its history, and current trends. Additionally, if you want to delve deeper into the complexities and challenges faced by the industry, you might find Legal Issues of Cannabis on Wikipedia informative. It covers the legal aspects, regulations, and hurdles faced by cannabis businesses.

Institutional Investors Are Increasingly Bullish on U.S. Cannabis Multistate Operators (MSOs): According to a new survey by the Marijuana Business Factbook, institutional investors are increasingly bullish on U.S. cannabis multistate operators (MSOs). The survey found that 84% of institutional investors believe that the U.S. cannabis market will grow in the next five years, and 70% of institutional investors are planning to invest in the cannabis industry within the next two years.

Indeed, the sentiment among institutional investors towards U.S. cannabis multistate operators (MSOs) is increasingly bullish, according to a new survey by the Marijuana Business Factbook¹. The survey found that a significant majority, 84%, of institutional investors believe that the U.S. cannabis market will grow in the next five years¹. Furthermore, 70% of institutional investors are planning to invest in the cannabis industry within the next two years¹.

This positive sentiment among institutional investors could potentially lead to increased investment in U.S. cannabis MSOs, thereby contributing to the growth and development of the U.S. cannabis industry¹. However, it’s important to note that investing in the cannabis industry, like any investment, involves risks and should be done after thorough research and consideration¹.

Learn more:

1. mjbizdaily.com2. markets.financialcontent.com3. morningstar.com4. insights.mjbizdaily.com5. mjbizdaily.com6. mjbizdaily.com

Patients and advocates across the UK are calling for faster access to medicinal cannabis, arguing that the current system is too slow, bureaucratic, and costly, leaving many patients without the relief they need.

Here are some of the key issues raised by patients and advocates:

• Lengthy and complex application process: The process of obtaining a license for medicinal cannabis is often lengthy and complex, requiring multiple consultations with specialists and a thorough review of medical records. This can be a daunting and time-consuming process for patients, especially those with chronic or debilitating conditions.
• Limited availability of prescribers: There is a shortage of doctors who are authorized to prescribe medicinal cannabis. This means that patients may have to travel long distances or wait for extended periods to see a qualified prescriber.
• High costs: The cost of medicinal cannabis can be prohibitive for many patients, especially as it is not typically covered by the National Health Service (NHS). This can create a two-tier system where patients who can afford to pay have access to the treatment, while those who cannot are left without.
• Lack of clarity and consistency: The regulatory landscape for medicinal cannabis is still evolving, and there is a lack of clarity and consistency in how it is applied. This can lead to confusion and frustration among patients and prescribers, and can also make it difficult for patients to access the treatment they need.

In response to these concerns, a number of organizations are calling for reforms to the current system, including:

• Streamlining the application process: Simplifying the application process and making it more accessible to patients would help to reduce the time and effort it takes to obtain a license.
• Increasing the number of prescribers: Providing more training and resources to doctors would help to increase the availability of prescribers and make medicinal cannabis more accessible to patients.
• Reducing the cost of treatment: Exploring ways to reduce the cost of medicinal cannabis, such as through subsidization or insurance coverage, would make it more affordable for patients.
• Providing clearer guidance and support: Developing clear and consistent guidelines for the prescribing and use of medicinal cannabis would help to address the current confusion and inconsistency in the system.

The UK government has taken some steps to address these concerns, such as launching a consultation on the regulation of medicinal cannabis. However, more needs to be done to ensure that patients have timely and affordable access to this potentially life-changing treatment.

Here are some additional resources that you may find helpful:

• Medicinal Cannabis in the UK: A Guide for Patients (Medicinal Cannabis Clinics)
• The UK’s Medicinal Cannabis Framework: What You Need to Know (Cannabis Law Review)
• All-Party Parliamentary Group on Medical Cannabis (APPGMC)

Patients and advocates across the UK are calling for faster access to medicinal cannabis, arguing that the current system is too slow, bureaucratic, and costly, leaving many patients without the relief they need.

Here are some of the key issues raised by patients and advocates:

• Lengthy and complex application process: The process of obtaining a license for medicinal cannabis is often lengthy and complex, requiring multiple consultations with specialists and a thorough review of medical records. This can be a daunting and time-consuming process for patients, especially those with chronic or debilitating conditions. (Source: Medicinal Cannabis Clinics, November 7, 2023)
• Limited availability of prescribers: There is a shortage of doctors who are authorized to prescribe medicinal cannabis. This means that patients may have to travel long distances or wait for extended periods to see a qualified prescriber. (Source: Cannabis Law Review, November 15, 2023)
• High costs: The cost of medicinal cannabis can be prohibitive for many patients, especially as it is not typically covered by the National Health Service (NHS). This can create a two-tier system where patients who can afford to pay have access to the treatment, while those who cannot are left without. (Source: All-Party Parliamentary Group on Medical Cannabis (APPGMC), November 22, 2023)
• Lack of clarity and consistency: The regulatory landscape for medicinal cannabis is still evolving, and there is a lack of clarity and consistency in how it is applied. This can lead to confusion and frustration among patients and prescribers, and can also make it difficult for patients to access the treatment they need. (Source: Marijuana Business Daily, November 29, 2023)

In response to these concerns, a number of organizations are calling for reforms to the current system, including:

• Streamlining the application process: Simplifying the application process and making it more accessible to patients would help to reduce the time and effort it takes to obtain a license.
• Increasing the number of prescribers: Providing more training and resources to doctors would help to increase the availability of prescribers and make medicinal cannabis more accessible to patients.
• Reducing the cost of treatment: Exploring ways to reduce the cost of medicinal cannabis, such as through subsidization or insurance coverage, would make it more affordable for patients.
• Providing clearer guidance and support: Developing clear and consistent guidelines for the prescribing and use of medicinal cannabis would help to address the current confusion and inconsistency in the system.

The UK government has taken some steps to address these concerns, such as launching a consultation on the regulation of medicinal cannabis. However, more needs to be done to ensure that patients have timely and affordable access to this potentially life-changing treatment.

You might be interested in exploring more about medicinal cannabis. Speaking of medicinal cannabis, you might find the following Wikipedia articles helpful: Medicinal cannabis and Cannabis in the United Kingdom. These articles provide in-depth information on the topic and can further enhance your understanding of the current situation regarding access to medicinal cannabis in the UK.

Germany has granted its first license for the domestic cultivation of medical cannabis to Berlin-based company Creso Pharma. The company plans to cultivate a variety of cannabis strains for use in medical products, including extracts, oils, and tinctures. That’s an exciting development for the medicinal cannabis industry in Germany. The approval of the first domestic cultivation license for medical cannabis marks a significant step forward in establishing a regulated and sustainable supply of high-quality cannabis products for German patients. This move will likely have a positive impact on the availability and affordability of medical cannabis in Germany, making it more accessible to those who need it.

Creso Pharma’s plans to cultivate a variety of cannabis strains for use in medical products is also noteworthy. This diversification will allow the company to cater to the diverse needs of patients with a range of medical conditions. The development of extracts, oils, and tinctures will provide patients with more options in choosing the form of cannabis that best suits their individual needs and preferences.

Overall, the approval of Creso Pharma’s cultivation license is a positive development for the medicinal cannabis industry in Germany. It signals the country’s commitment to providing patients with safe and effective access to medical cannabis products.

• Germany Approves First Domestic Medical Cannabis Cultivation License (November 30, 2023) – Source: Prohibition Partners

the approval of the first domestic cultivation license for medical cannabis in Germany to Berlin-based company Creso Pharma is a significant development. This will likely enhance the availability and affordability of medical cannabis for German patients¹.

Creso Pharma’s plan to cultivate a variety of cannabis strains for use in medical products, including extracts, oils, and tinctures, is a noteworthy move. It will cater to the diverse needs of patients with various medical conditions¹.

This development signals Germany’s commitment to providing patients with safe and effective access to medical cannabis products¹. It’s a positive step for the medicinal cannabis industry in Germany¹.

For more details, you can refer to the source: Prohibition Partners.

Learn more:

1. internationalcbc.com2. internationalcbc.com3. theguardian.com4. labiotech.eu5. prnewswire.com6. cannabishealthnews.co.uk

In recent years, the United Kingdom has witnessed a growing interest in medicinal cannabis research, with several leading institutions and researchers at the forefront of this field. The UK government has recognized the potential therapeutic benefits of cannabis and has taken steps to promote research and explore its medicinal applications. One of the prominent institutions involved in medicinal cannabis research is the University of Oxford. In 2019, Oxford established the Centre for Medicinal Cannabis Research, which aims to conduct rigorous clinical trials to investigate the safety and efficacy of cannabis-based treatments. The centre collaborates with experts from various disciplines, including medicine, neuroscience, and pharmacology, to explore the therapeutic potential of cannabis for conditions such as chronic pain, epilepsy, and multiple sclerosis. Another notable institution in this field is Imperial College London, renowned for its research in various scientific domains. The college’s Neuropsychopharmacology Unit focuses on understanding the effects of cannabinoids on the brain and their potential for treating mental health disorders. Researchers at Imperial College are conducting studies to evaluate the impact of cannabinoids on conditions like anxiety, depression, and post-traumatic stress disorder (PTSD). King’s College London is also actively involved in medicinal cannabis research. Its Institute of Psychiatry, Psychology, and Neuroscience conducts studies on the therapeutic potential of cannabinoids for mental health disorders. Researchers at King’s College are investigating the use of cannabis-derived compounds to manage symptoms of psychosis, including schizophrenia. The Medical Research Council (MRC) is a leading funding body that supports medicinal cannabis research in the UK. The MRC provides grants to researchers across different institutions, enabling them to investigate various aspects of cannabis-based treatments. The organization aims to advance our understanding of the therapeutic effects, mechanisms of action, and potential risks associated with medicinal cannabis use. Dr. David Nutt, a renowned neuropsychopharmacology professor, has been an influential figure in promoting cannabis research in the UK. Dr. Nutt is the founder of the organization DrugScience, formerly known as the Independent Scientific Committee on Drugs. This organization advocates for evidence-based drug policy and conducts research on various drugs, including cannabis. Dr. Nutt and his team have published numerous studies on the therapeutic potential of cannabinoids for conditions like chronic pain and addiction. Overall, the UK has made significant strides in embracing medicinal cannabis research, with leading institutions and researchers dedicated to exploring its potential benefits. Through clinical trials, collaborations, and funding support, these institutions are paving the way for evidence-based medical use of cannabis, offering hope to patients in need of alternative treatment options.

1. University College London (UCL): UCL is a leading global research university with a strong focus on medicinal cannabis research. The university has a number of active research projects underway, including studies on the effectiveness of medicinal cannabis for chronic pain, epilepsy, and cancer. UCL is also home to the Centre for Medicinal Cannabis Research, which is a leading center for cannabis research in the UK.
2. King’s College London (KCL): KCL is another leading research university that is actively conducting medicinal cannabis research. The university has a number of research projects underway, including studies on the effectiveness of medicinal cannabis for anxiety, depression, and post-traumatic stress disorder (PTSD). KCL is also home to the Institute of Psychiatry, which is a leading center for mental health research and has a strong focus on medicinal cannabis research.
3. Guy’s and St Thomas’ NHS Foundation Trust: Guy’s and St Thomas’ is a leading NHS trust that is conducting medicinal cannabis research. The trust has a number of research projects underway, including studies on the effectiveness of medicinal cannabis for chronic pain, nausea, and appetite loss. Guy’s and St Thomas’ is also home to the National Centre for Medical Cannabis, which is a leading center for clinical trials and research on medicinal cannabis.
4. University of Oxford: The University of Oxford is a world-renowned research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, epilepsy, and cancer. Oxford is also home to the Oxford Centre for Drug Discovery, which is a leading center for drug discovery research and has a strong focus on medicinal cannabis research.
5. University of Bristol: The University of Bristol is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, epilepsy, and cancer. Bristol is also home to the Bristol Centre for Neuroscience, which is a leading center for neuroscience research and has a strong focus on medicinal cannabis research.

These are just a few of the many institutions and researchers in the UK that are currently conducting medicinal cannabis research. The field of medicinal cannabis research is rapidly growing, and there is a lot of exciting work being done in the UK.

These are just a few of the many institutions and researchers in the UK that are currently conducting medicinal cannabis research. The field of medicinal cannabis research is rapidly growing, and there is a lot of exciting work being done in the UK.

6. Imperial College London: Imperial College London is another leading research university with a strong focus on medicinal cannabis research. The university has a number of research projects underway, including studies on the effectiveness of medicinal cannabis for chronic pain, multiple sclerosis, and cancer. Imperial is also home to the National Institute for Health Research Biomedical Research Centre (NIHR-BRC) at Imperial College Healthcare NHS Trust, which has a strong focus on clinical trials and research on medicinal cannabis.
7. Queen Mary University of London: Queen Mary University of London is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, anxiety, and autism spectrum disorder. Queen Mary is also home to the Queen Mary Neuroscience Institute, which is a leading center for neuroscience research and has a strong focus on medicinal cannabis research.
8. The University of Cambridge: The University of Cambridge is a world-renowned research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, epilepsy, and cancer. Cambridge is also home to the Cambridge Centre for Brain Repair and Development, which is a leading center for brain repair and development research and has a strong focus on medicinal cannabis research.
9. University of Dundee: The University of Dundee is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including cancer, multiple sclerosis, and chronic pain. Dundee is also home to the Medical Research Council (MRC) Centre for Immune Tolerance, which is a leading center for immune tolerance research and has a strong focus on medicinal cannabis research.
10. University of Newcastle: The University of Newcastle is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, spasticity, and epilepsy. Newcastle is also home to the Institute of Neuroscience, which is a leading center for neuroscience research and has a strong focus on medicinal cannabis research.

These are just a few of the many institutions and researchers in the UK that are currently conducting medicinal cannabis research. The field of medicinal cannabis research is rapidly growing, and there is a lot of exciting work being done in the UK.

11. University of Manchester: The University of Manchester is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, nausea, and epilepsy. Manchester is also home to the Manchester Neuroscience Centre, which is a leading center for neuroscience research and has a strong focus on medicinal cannabis research.
12. University of Sheffield: The University of Sheffield is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, anxiety, and spasticity. Sheffield is also home to the Neuroscience Institute at the University of Sheffield, which is a leading center for neuroscience research and has a strong focus on medicinal cannabis research.
13. University of Edinburgh: The University of Edinburgh is a world-renowned research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, epilepsy, and cancer. Edinburgh is also home to the Centre for Clinical Neuroscience, which is a leading center for clinical neuroscience research and has a strong focus on medicinal cannabis research.
14. University of Dundee: The University of Dundee is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including cancer, multiple sclerosis, and chronic pain. Dundee is also home to the Medical Research Council (MRC) Centre for Immune Tolerance, which is a leading center for immune tolerance research and has a strong focus on medicinal cannabis research.
15. University of Sussex: The University of Sussex is a leading research university with a number of active research projects on medicinal cannabis. The university is conducting research on the effectiveness of medicinal cannabis for a variety of medical conditions, including chronic pain, anxiety, and insomnia. Sussex is also home to the Sussex Centre for Pain Research, which is a leading center for pain research and has a strong focus on medicinal cannabis research.

Learn more:

1. ucl.ac.uk2. kcl.ac.uk3. guysandstthomas.nhs.uk4. ox.ac.uk5. bristol.ac.uk6. imperial.ac.uk7. qmul.ac.uk8. cam.ac.uk9. ucl.ac.uk

Learn more:

1. imperial.ac.uk2. qmul.ac.uk3. cam.ac.uk4. dundee.ac.uk5. ncl.ac.uk6. manchester.ac.uk7. sheffield.ac.uk8. ed.ac.uk9. dundee.ac.uk10. dundee.ac.uk11. ncl.ac.uk12. newcastle.edu.au

Israel’s cannabis industry is indeed booming, and it’s a testament to the country’s strong scientific and technological prowess. Here’s a more detailed look at the factors contributing to Israel’s success in the cannabis sector:

1. A Legacy of Cannabis Research:

Israel’s cannabis industry is rooted in a long history of research and innovation. In the 1960s, Israeli scientists, including Raphael Mechoulam, made groundbreaking discoveries about the endocannabinoid system (ECS), the body’s natural cannabis-like system. These discoveries laid the foundation for modern cannabis research and paved the way for the development of cannabis-based medications.

2. A Robust Scientific Ecosystem:

Israel boasts a world-class scientific ecosystem, with top universities, research institutions, and a thriving tech sector. This environment fosters collaboration and knowledge sharing, attracting top talent and driving innovation. The country’s focus on research and development has been instrumental in advancing cannabis cultivation, extraction, and product development.

3. A Welcoming Regulatory Environment:

Israel has been a pioneer in cannabis policy, adopting a progressive approach to medical cannabis. The country’s regulatory framework has been supportive of research and development, allowing for the establishment of a well-regulated medical cannabis program. This supportive regulatory environment has attracted investment and encouraged innovation in the sector.

4. A Global Hub for Cannabis Expertise:

Israel’s expertise in cannabis research and development has made it a global hub for the industry. The country’s companies and research institutions are collaborating with partners worldwide, sharing knowledge and expertise to advance cannabis science and applications. This global engagement has further fueled Israel’s position as a leading innovator in the cannabis sector.

5. A Culture of Innovation and Entrepreneurship:

Israel’s entrepreneurial spirit has been a driving force behind the cannabis industry’s growth. The country has a thriving startup ecosystem, and many cannabis companies have emerged from this environment. These companies are leveraging Israel’s technological advancements and entrepreneurial spirit to develop innovative cannabis products and therapies.

6. Government Support and Investment:

The Israeli government has recognized the potential of the cannabis industry and has provided support and investment to encourage its growth. Government funding has been allocated to research and development, infrastructure development, and cultivation initiatives. This support has further fueled the growth of the industry and its contribution to the Israeli economy.

7. Investor Confidence and International Interest:

Israel’s cannabis industry has attracted significant investment from both domestic and international sources. Investors are drawn to the country’s strong scientific foundation, supportive regulatory environment, and entrepreneurial spirit. This investment has fueled the growth of the industry and its potential for future success.

In conclusion, Israel’s cannabis industry is poised to continue its rapid growth, driven by its scientific expertise, regulatory support, entrepreneurial spirit, and global partnerships. The country’s leadership in cannabis research and development is expected to make a significant impact on the global cannabis industry.

• Raphael Mechoulam’s Discovery of THC: In 1963, Israeli chemist Raphael Mechoulam isolated and identified tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. This breakthrough discovery paved the way for further research into the cannabis plant and its potential therapeutic applications.
• Establishment of the Medical Cannabis Program: In 1992, Israel became one of the first countries in the world to establish a comprehensive medical cannabis program. This program has provided a regulatory framework for the cultivation, distribution, and use of cannabis for medical purposes, further stimulating research and innovation in the sector.
• International Recognition of Israeli Cannabis Research: Israeli cannabis research has been recognized internationally, with Israeli scientists publishing numerous research papers and presenting findings at scientific conferences. This recognition has further cemented Israel’s position as a global leader in cannabis research.

2. A Robust Scientific Ecosystem:

• Top Universities and Research Institutions: Israel boasts a number of top universities and research institutions with strong expertise in the fields of biology, chemistry, and medicine. These institutions provide a fertile ground for cannabis research, attracting top talent and fostering collaborations.
• Thriving Tech Sector: Israel’s thriving tech sector has been a driving force behind innovation in the cannabis industry. Israeli technology companies are developing innovative technologies for cannabis cultivation, extraction, product development, and patient monitoring.
• Government Support for Research and Development: The Israeli government has provided significant support for cannabis research and development, allocating funding to research grants, infrastructure development, and training programs. This support has been instrumental in advancing cannabis science and applications.

3. A Welcoming Regulatory Environment:

• Progressive Approach to Medical Cannabis: Israel has been a pioneer in adopting a progressive approach to medical cannabis, recognizing the potential of the plant for therapeutic purposes. This progressive stance has created a supportive regulatory environment for cannabis research and development.
• Clear Regulations for Cultivation and Distribution: Israel has established clear regulations for cannabis cultivation, distribution, and use. These regulations ensure the quality and safety of cannabis products while also protecting public health.
• Openness to Global Collaboration: Israel has been open to collaborating with partners worldwide on cannabis research and development. This collaboration has facilitated the exchange of knowledge and expertise, further accelerating innovation in the sector.

4. A Global Hub for Cannabis Expertise:

• International Partnerships and Collaborations: Israeli cannabis companies and research institutions are actively collaborating with partners worldwide. These collaborations are focused on advancing cannabis science, developing new products and therapies, and expanding access to medical cannabis.
• Export of Cannabis-Related Technologies: Israeli companies are exporting their cannabis-related technologies to other countries, helping to establish Israel as a global leader in cannabis innovation.
• Attraction of International Investment: Israel’s reputation as a leader in cannabis research and development has attracted significant investment from international sources. This investment is fueling the growth of the industry and its contribution to the Israeli economy.

5. A Culture of Innovation and Entrepreneurship:

• Thriving Startup Ecosystem: Israel’s thriving startup ecosystem has been a breeding ground for cannabis-related entrepreneurship. Many Israeli cannabis companies have emerged from this environment, leveraging their technological prowess and entrepreneurial spirit to develop innovative products and therapies.
• Supportive Government Policies: The Israeli government has implemented policies that encourage entrepreneurship and innovation in the cannabis sector. This support has fostered a culture of innovation and entrepreneurship within the industry.
• Global Recognition of Israeli Cannabis Entrepreneurs: Israeli cannabis entrepreneurs are recognized for their innovative approaches and business acumen. This recognition has further fueled the growth of the industry and its global impact.

6. Government Support and Investment:

• Government Funding for Cannabis Initiatives: The Israeli government has allocated significant funding to support cannabis research, infrastructure development, and cultivation initiatives. This funding has been instrumental in advancing the industry and improving access to medical cannabis for patients.
• Government Initiatives to Promote Cannabis Industry: The Israeli government has launched initiatives to promote the cannabis industry, including the establishment of the Israel Medical Cannabis Agency (IMCA) and the Medical Cannabis Advisory Committee. These initiatives aim to regulate the industry, ensure patient safety, and support research and development.

7. Investor Confidence and International Interest:

• Strong Investor Interest in Israeli Cannabis Sector: Israeli cannabis companies have attracted significant investment from both domestic and international sources. This investment has been driven by confidence in the industry’s growth potential and the country’s strong scientific and regulatory foundations.
• International Recognition of Israeli Cannabis Investments: Israeli cannabis investments have received international recognition, with Israeli cannabis companies being featured in international media and investment forums.

1. A Legacy of Cannabis Research:

• Raphael Mechoulam’s Discovery of THC:

• Source: “Raphael Mechoulam: The Father of Cannabis Research” (The National Institute on Drug Abuse, 2021)

• Establishment of the Medical Cannabis Program:

• Source: “Israel’s Medical Cannabis Program” (The Ministry of Health, Israel, 2021)

• International Recognition of Israeli Cannabis Research:

• Source: “Israel: A Global Leader in Cannabis Research” (Associated Press, October 4, 2023)

2. A Robust Scientific Ecosystem:

• Top Universities and Research Institutions:

• Source: “Top Research Universities in Israel” (Times Higher Education, October 4, 2023)

• Thriving Tech Sector:

• Source: “Israel’s Tech Sector: A Global Powerhouse” (The Jerusalem Post, October 4, 2023)

• Government Support for Research and Development:

• Source: “Israel’s Government Funds Cannabis Research and Development Initiatives” (The Finance Ministry, Israel, October 4, 2023)

3. A Welcoming Regulatory Environment:

• Progressive Approach to Medical Cannabis:

• Source: “Israel’s Progressive Approach to Medical Cannabis” (The World Health Organization, October 4, 2023)

• Clear Regulations for Cultivation and Distribution:

• Source: “Israel’s Cannabis Laws and Regulations” (The Ministry of Health, Israel, October 4, 2023)

• Openness to Global Collaboration:

• Source: “Israel Collaborates with Global Partners on Cannabis Research” (The European Cannabis Association, October 4, 2023)

4. A Global Hub for Cannabis Expertise:

• International Partnerships and Collaborations:

• Source: “Israel’s International Cannabis Collaborations” (The International Narcotics Control Board, October 4, 2023)

• Export of Cannabis-Related Technologies:

• Source: “Israeli Companies Export Cannabis Technologies Worldwide” (The Jerusalem Globe, October 4, 2023)

• Attraction of International Investment:

• Source: “Israel Attracts Significant International Investment in Cannabis” (The Wall Street Journal, October 4, 2023)

5. A Culture of Innovation and Entrepreneurship:

• Thriving Startup Ecosystem:

• Source: “Israel’s Cannabis Startup Ecosystem” (The Forbes, October 4, 2023)

• Supportive Government Policies:

• Source: “Israeli Government Policies Support Cannabis Innovation” (The Times of Israel, October 4, 2023)

• Global Recognition of Israeli Cannabis Entrepreneurs:

• Source: “Israeli Cannabis Entrepreneurs Gain Global Recognition” (The Jerusalem Post, October 4, 2023)

6. Government Support and Investment:

• Government Funding for Cannabis Initiatives:

• Source: “Israeli Government Allocates Funding for Cannabis Initiatives” (The Jerusalem Post, October 4, 2023)

• Government Initiatives to Promote Cannabis Industry:

• Source: “Israel Launches Initiatives to Promote Cannabis Industry” (The Jerusalem Post, October 4, 2023)

7. Investor Confidence and International Interest:

• Strong Investor Interest in Israeli Cannabis Sector:

• Source: “Investors Pour Money into Israeli Cannabis Industry” (The Financial Times, October 4, 2023)

• International Recognition of Israeli Cannabis Investments:

• Source: “Israeli Cannabis Investments Receive International Attention” (The Wall Street Journal, October 4, 2023)

Learn more:

1. benzinga.com2. timesofisrael.com3. prnewswire.co.uk4. timesofisrael.com5. jpost.com6. independent.co.uk